INMB · Inmune Bio, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $50.0K | $14.0K | $155.0K | $374.0K | $181.0K | $10.9K |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $20.66M | $33.17M | $20.27M | $17.07M | $20.54M | $5.92M |
| SG&A | $10.26M | $9.48M | $9.62M | $9.26M | $8.79M | $6.32M |
| Total Operating Expenses | $47.43M | $42.65M | $29.90M | $26.32M | $29.33M | $12.24M |
| D&A | $84.0K | - | - | - | - | - |
| Operating Income | ($47.38M) | ($42.63M) | ($29.74M) | ($25.95M) | ($29.15M) | ($12.23M) |
| Interest Expense | $789.0K | $789.0K | $2.01M | $985.0K | - | - |
| Income Tax | - | - | - | - | - | - |
| Net Income | ($45.93M) | ($42.08M) | ($30.01M) | ($27.30M) | ($30.34M) | ($12.10M) |
| EPS - Basic | ($1.86) | ($2.11) | ($1.67) | ($1.88) | - | - |
| EPS - Diluted | ($1.86) | ($2.11) | ($1.67) | ($1.88) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $24.75M | $20.92M | $35.85M | $52.15M | $74.81M | $21.97M |
| Accounts Receivable | $4.28M | $1.18M | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - |
| Current Assets | $29.89M | $22.66M | $39.94M | $64.67M | $82.61M | $23.99M |
| Total Assets | $32.35M | $39.56M | $57.00M | $81.80M | $99.94M | $40.66M |
| Current Liabilities | $8.42M | $7.22M | $18.46M | $10.92M | $4.36M | $1.78M |
| Long-term Debt | - | $15.00M | $9.70M | $15.00M | - | - |
| Total Liabilities | $8.83M | $7.46M | $18.86M | $21.69M | $19.72M | $1.90M |
| Stockholders' Equity | $23.52M | $32.10M | $37.34M | $60.10M | $80.22M | $38.75M |
| Retained Earnings | ($209.04M) | ($163.10M) | ($121.02M) | ($91.01M) | ($63.72M) | ($33.38M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($22.58M) | ($33.36M) | ($11.98M) | ($22.69M) | ($28.50M) | ($8.94M) |
| Investing Cash Flow | ($1.04M) | - | - | - | ($15.00M) | - |
| Financing Cash Flow | $27.61M | $18.21M | ($4.22M) | $729.0K | $96.36M | $23.90M |
| CapEx | $1.04M | - | - | - | - | - |
| Free Cash Flow | ($23.62M) | - | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -94766.0% | -304535.7% | -19187.7% | -6938.8% | -16106.6% | -112016.1% |
| EBITDA margin | -94598.0% | - | - | - | - | - |
| Net margin | -91866.0% | -300585.7% | -19360.0% | -7299.2% | -16762.4% | -110838.8% |
| Free cash flow margin | -47248.0% | - | - | - | - | - |
| FCF / Net income | 0.51 | - | - | - | - | - |
| R&D / Revenue | 41318.0% | 236900.0% | 13079.4% | 4563.4% | 11349.7% | 54209.4% |
| SG&A / Revenue | 20520.0% | 67735.7% | 6208.4% | 2475.4% | 4856.9% | 57906.7% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -142.0% | -106.4% | -52.6% | -33.4% | -30.4% | -29.8% |
| Return on equity | -195.3% | -131.1% | -80.4% | -45.4% | -37.8% | -31.2% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 3.55 | 3.14 | 2.16 | 5.92 | 18.95 | 13.50 |
| Quick ratio | 3.55 | 3.14 | 2.16 | 5.92 | 18.95 | 13.50 |
| Cash ratio | 2.94 | 2.90 | 1.94 | 4.78 | 17.16 | 12.37 |
| Leverage | ||||||
| Debt / Equity | - | 0.47 | 0.26 | 0.25 | - | - |
| Debt / Assets | - | 0.38 | 0.17 | 0.18 | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -60.1x | -54.0x | -14.8x | -26.3x | - | - |
| Equity multiplier | 1.38 | 1.23 | 1.53 | 1.36 | 1.25 | 1.05 |
| Liabilities / Assets | 0.27 | 0.19 | 0.33 | 0.27 | 0.20 | 0.05 |
| Efficiency | ||||||
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 31273d | 30790d | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 1.6x | 2.9x | 5.4x | 1.7x | - | - |
| P / S | 772.4x | 6652.8x | 1306.2x | 273.4x | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 257.1% | -91.0% | -58.6% | 106.6% | 1558.1% | - |
| Revenue CAGR (3y) | -48.9% | -57.4% | 142.2% | - | - | - |
| Revenue CAGR (5y) | 35.6% | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -11.1% | -43.4% | -14.6% | 11.0% | -138.4% | -57.7% |
| Net income growth (YoY) | -9.2% | -40.2% | -9.9% | 10.0% | -150.8% | -57.6% |
| EPS growth (YoY) | 11.8% | -26.3% | 11.2% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -26.7% | -14.0% | -37.9% | -25.1% | 107.0% | 64.1% |
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-8.43
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Inmune Bio against the 5 most active filers in the same SIC group.